Qianjiang Yongan Pharmaceutical Co Ltd (002365) — Cash Flow Reinvestment Rate
Qianjiang Yongan Pharmaceutical Co Ltd (002365) has a Cash Flow Reinvestment Rate of 0.20x as of September 2025, reinvesting CN¥11.85 Million (capex CN¥11.85 Million ) from operating cash flow of CN¥58.18 Million. See Qianjiang Yongan Pharmaceutical Co Ltd free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Qianjiang Yongan Pharmaceutical Co Ltd Cash Flow Reinvestment Rate (2006–2024)
Historical reinvestment intensity for Qianjiang Yongan Pharmaceutical Co Ltd across 19 annual periods. For the full cash flow conversion analysis, see Qianjiang Yongan Pharmaceutical Co Ltd (002365) cash flow conversion.
Annual Cash Flow Reinvestment Rate for Qianjiang Yongan Pharmaceutical Co Ltd (2006–2024)
Year-by-year capital reinvestment analysis for Qianjiang Yongan Pharmaceutical Co Ltd. See how financially flexible is Qianjiang Yongan Pharmaceutical Co Ltd to measure the company's free cash flow as a share of total liabilities.
| Year | Reinvestment Rate | Total Reinvested (CNY) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2024 | 1.77x | CN¥186.81 Million | CN¥105.71 Million | CN¥118.04 Million | ▲ +128.2% |
| 2023 | 0.77x | CN¥189.15 Million | CN¥244.26 Million | CN¥120.74 Million | ▲ +16.4% |
| 2022 | 0.67x | CN¥257.76 Million | CN¥387.28 Million | CN¥149.07 Million | ▼ -58.9% |
| 2021 | 1.62x | CN¥165.02 Million | CN¥101.81 Million | CN¥63.05 Million | ▼ -4.6% |
| 2020 | 1.70x | CN¥351.06 Million | CN¥206.66 Million | CN¥104.41 Million | ▲ +98.9% |
| 2019 | 0.85x | CN¥204.59 Million | CN¥239.55 Million | CN¥134.39 Million | ▼ -38.0% |
| 2018 | 1.38x | CN¥432.37 Million | CN¥314.02 Million | CN¥269.50 Million | ▼ -11.4% |
| 2017 | 1.55x | CN¥306.65 Million | CN¥197.32 Million | CN¥289.47 Million | ▲ +29.0% |
| 2016 | 1.20x | CN¥101.83 Million | CN¥84.53 Million | CN¥40.13 Million | ▲ +149.3% |
| 2015 | 0.48x | CN¥34.12 Million | CN¥70.61 Million | CN¥34.12 Million | ▼ -81.6% |
| 2014 | 2.63x | CN¥50.69 Million | CN¥19.26 Million | CN¥50.69 Million | ▲ +67.6% |
| 2013 | 1.57x | CN¥99.93 Million | CN¥63.65 Million | CN¥99.93 Million | ▼ -7.6% |
| 2012 | 1.70x | CN¥120.18 Million | CN¥70.75 Million | CN¥120.18 Million | ▼ -37.5% |
| 2011 | 2.72x | CN¥248.03 Million | CN¥91.23 Million | CN¥248.03 Million | ▲ +14.6% |
| 2010 | 2.37x | CN¥104.52 Million | CN¥44.06 Million | CN¥104.52 Million | ▲ +87.9% |
| 2009 | 1.26x | CN¥45.98 Million | CN¥36.43 Million | CN¥45.98 Million | ▲ +177.0% |
| 2008 | 0.46x | CN¥72.19 Million | CN¥158.47 Million | CN¥72.19 Million | ▼ -54.2% |
| 2007 | 0.99x | CN¥60.77 Million | CN¥61.08 Million | CN¥60.77 Million | ▲ +75.1% |
| 2006 | 0.57x | CN¥17.68 Million | CN¥31.11 Million | CN¥17.68 Million | — |